EKITA Meeting_Strategies for improving allograft and patient survival after kidney transplantation
*** Online Registrations are currently Closed***
Registrations will be available again at the registration desk onsite
For more information please contact: firstname.lastname@example.org
The EKITA Meeting is held during the TLJ (Transplantation Learning Journey) Week.
Click here to learn more about TLJ2018 and the educational opportunities
EKITA is the official representative body of kidney transplantation in Europe on behalf of ESOT.
The EKITA Board is proud to announce a fresh new appointment for 2018, calling for the participation of all those working and involved in the field of kidney transplantation. This new educational activity aims to provide a forum for those working in the field of kidney transplantation to exchange scientific information and views related primarily to providing the best service for patients in Europe requiring kidney transplantation.
The meeting will stimulate and foster new developments in the area of kidney transplantation in all fields: training, organ exchange, cooperative clinical and translational research projects.
• Kidney paired live donation: Given the relative small populations in some of the European countries, the pool for KPD programs is limited. Thus action is needed to extend KPD programs across national borders. This important point will be thoroughly discussed from a scientific/clinical but also ethical and legal point of view.
• Donor organ preservation and organ quality: Some European countries use machine perfusion systems for donor kidneys, some not, some only for selected donors (eg DCD). This session will elucidate the evidence for or against this technique but will also evaluate the effectiveness of other donor interventions such as hypothermia, steroid treatment and its effects on DGF and mid to long term outcomes.
• Alloimmunity - What‘s Hot & New: This key session will span the whole spectrum from HLA- and non-HLA alloimmunity, matching strategies up to interventional studies on BCAR of the naïve and sensitized patient.
• The elderly patient: Balancing survival with graft attrition is key to avoid futility in an era of scarce donor organ resources. Although all studies even in the very elderly show a survival benefit and cost effectiveness compared to dialysis, it is time to reevaluate this paradigm in times where dialysis became considerably cheaper and deceased donor organs of considerably lower quality for this recipient population, i.e. the VECD & VECR (the Very Expanded Criteria Donor & Recipient).
After attending this meeting, participants will be able to:
• Get a clear picture of the kidney transplant network in Europe and existing challenges and opportunities for improvement and transnational collaborations (from KPD to clinical studies on treatmet of the alloimmune response)
• Evaluate the studies of donor and donor organ pretreatment and outcomes and derive an own opinion on the cost/effectiveness of these procedures.
• To derive patient tailored algorithms for the in depth diagnosis and potential therapeutic options and effectiveness of intervention in challenging areas such as ABMR.
• Get a clear picture about the challenges and risks and policies available for the management of the ‘third-’ and ‘fourth age’ transplant candidates.
This meeting is designed for kidney transplant specialist, i.e transplant surgeons, nephrologists, tissue typers, renal pathologists. Researches in the area will have the opportunity to engage with clinically working colleagues to establish translational projects.